Scholarlink

<p>Neurofibromatosis type 1 (NF1) is a genetic disorder affecting 1 in 3 000 people due to heterozygous mutations in the <i>NF1</i> gene. Patients with NF1 can develop multiple symptoms, such as neurofibromas, skin hyperpigmentation, and bone abnormalities, including tibial pseudarthrosis and spine deformity. Here, we aimed to elucidate the cellular origin and pathogenic mechanism of NF1 spine deformity. We explored the <i>Prss56-Nf1</i> knockout (KO) mouse model that recapitulates neurofibromas and pseudarthrosis by carrying <i>Nf1</i> gene inactivation in Prss56-expressing boundary cap cells, a neural crest subset, and their derivatives. Micro-CT analyses showed that <i>Prss56-Nf1</i> KO mice exhibit spine deformity from 12 months of age, associated with vertebral anomalies reminiscent of patients with NF1. Fate mapping revealed a significant increase in OSX<sup>+</sup> osteoblasts of the Prss56 lineage in vertebrae of <i>Prss56-Nf1</i> KO mice. Increased traced <i>Nf1</i>-deficient cells correlated with increased vertebral bone volume and kyphosis spine curvature. Finally, we showed that treating <i>Prss56-Nf1</i> KO mice with RAS-MAPK pathway inhibitors prevented spine deformity. Overall, the <i>Prss56-Nf1</i> KO mouse model unravels the role of osteoblasts from the Prss56 lineage as the cellular origin of NF1 spine deformity and highlights RAS-MAPK pathway inhibition as a promising therapeutic strategy for preventing NF1 spine deformity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmacological inhibition of RAS pathway alleviates spine deformity in a mouse model of neurofibromatosis type 1

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月16日

查看全文
  • Franceska Kovaci,
  • Cassandre Goachet,
  • Simon Perrin,
  • Lotfi Slimani,
  • Fanny Coulpier,
  • Françoise Tilotta,
  • Piotr Topilko,
  • Céline Colnot

摘要

Neurofibromatosis type 1 (NF1) is a genetic disorder affecting 1 in 3 000 people due to heterozygous mutations in the NF1 gene. Patients with NF1 can develop multiple symptoms, such as neurofibromas, skin hyperpigmentation, and bone abnormalities, including tibial pseudarthrosis and spine deformity. Here, we aimed to elucidate the cellular origin and pathogenic mechanism of NF1 spine deformity. We explored the Prss56-Nf1 knockout (KO) mouse model that recapitulates neurofibromas and pseudarthrosis by carrying Nf1 gene inactivation in Prss56-expressing boundary cap cells, a neural crest subset, and their derivatives. Micro-CT analyses showed that Prss56-Nf1 KO mice exhibit spine deformity from 12 months of age, associated with vertebral anomalies reminiscent of patients with NF1. Fate mapping revealed a significant increase in OSX+ osteoblasts of the Prss56 lineage in vertebrae of Prss56-Nf1 KO mice. Increased traced Nf1-deficient cells correlated with increased vertebral bone volume and kyphosis spine curvature. Finally, we showed that treating Prss56-Nf1 KO mice with RAS-MAPK pathway inhibitors prevented spine deformity. Overall, the Prss56-Nf1 KO mouse model unravels the role of osteoblasts from the Prss56 lineage as the cellular origin of NF1 spine deformity and highlights RAS-MAPK pathway inhibition as a promising therapeutic strategy for preventing NF1 spine deformity.